What are mast cells, their role in allergic reactions, and how are mast‑cell‑mediated conditions treated?

Mast Cells: Function, Role in Allergic Reactions, and Treatment of Mast Cell-Mediated Conditions

Mast cells are immune cells that release inflammatory mediators (histamine, tryptase, prostaglandins, leukotrienes) causing allergic reactions and systemic symptoms; treatment centers on blocking mediator release with H1/H2 antihistamines, avoiding triggers, and carrying epinephrine for anaphylaxis, with cytoreductive therapy reserved for advanced systemic mastocytosis.

What Are Mast Cells?

Mast cells are tissue-resident immune cells that serve as critical effectors in both allergic responses and innate immunity 1. They contain secretory granules packed with preformed mediators including histamine, heparin, tryptase, and proteases 2. When activated, mast cells rapidly degranulate and release these mediators, along with newly synthesized products like prostaglandin D2 and leukotriene C4 3.

Activation Mechanisms

Mast cells can be activated through multiple pathways 4:

• IgE-mediated (allergic): Allergen binding to IgE attached to FcεRI receptors—the classic allergic pathway 2
• Non-IgE mechanisms: Physical triggers (temperature extremes, pressure, vibration), neuropeptides, cytokines (especially IL-33), stress hormones, medications, and direct mast cell activators 5, 1

The ability of mast cells to respond to diverse non-allergic triggers explains why patients can experience symptoms without traditional allergies 5.

Role in Allergic Reactions

Mast cells are the primary effector cells in immediate hypersensitivity reactions 2. Upon allergen exposure in sensitized individuals, cross-linking of surface IgE triggers explosive degranulation within seconds to minutes 1. This releases:

• Histamine: Causes vasodilation, increased vascular permeability, bronchoconstriction, pruritus
• Tryptase: Marker of mast cell activation (peaks 30-120 minutes after reaction) 4
• Leukotrienes/Prostaglandins: Sustain bronchoconstriction and inflammation
• Cytokines: Drive Th2 responses and chronic allergic inflammation 2

Beyond immediate reactions, mast cells actively shape the allergic immune response by promoting Th2 differentiation and IgE synthesis 6, 2. They participate in chronic inflammatory diseases including asthma, rhinitis, atopic dermatitis, and urticaria 2.

Mast Cell-Mediated Conditions

Mastocytosis

Mastocytosis results from clonal proliferation of abnormal mast cells accumulating in skin and/or internal organs 7. The 2022 WHO/ICC classification includes:

• Cutaneous mastocytosis (CM): Skin-limited disease, common in children with excellent prognosis 8
• Systemic mastocytosis (SM): Extracutaneous organ involvement, subdivided into:
  • Indolent SM (ISM) and Smoldering SM (SSM)
  • Aggressive SM (ASM)
  • SM with associated hematologic neoplasm (SM-AHN)
  • Mast cell leukemia (MCL)

Diagnosis requires: 1 major criterion (≥15 mast cells in aggregates on biopsy) plus 1 minor criterion, OR 3 minor criteria. Minor criteria include: atypical mast cell morphology, KIT D816V mutation, aberrant CD25/CD2/CD30 expression, and serum tryptase >20 ng/mL 7.

Mast Cell Activation Syndrome (MCAS)

MCAS presents with episodic systemic anaphylaxis affecting ≥2 organ systems, with documented elevation of mast cell mediators (tryptase, histamine metabolites, prostaglandin D2 metabolites), and symptom improvement with antimediator therapy 3. This diagnosis requires excluding secondary causes (allergies, chronic inflammatory disorders) and clonal mast cell disease.

Hereditary Alpha-Tryptasemia

A recently recognized condition with TPSAB1 gene duplications/triplications causing elevated basal tryptase and symptoms including flushing, dysautonomia, gastrointestinal complaints, chronic pain, and joint hypermobility 4. Found in 4-6% of the general population.

Treatment Approach

For All Mast Cell-Mediated Conditions

The primary management goal is preventing mast cell activation and blocking mediator effects 8, 4.

1. Trigger Avoidance (Essential First Step)

Identify and avoid specific triggers 8:

• Temperature extremes (especially heat, less commonly cold)
• Physical trauma, friction, pressure
• Emotional stress and anxiety
• Specific medications (NSAIDs, opioids, certain anesthetics)
• Alcohol
• Insect stings
• Infections with fever

2. Antimediator Drug Therapy (Cornerstone of Treatment)

Stepwise approach for chronic symptom control 4:

First-line:

• H1 antihistamines: Control pruritus, flushing, urticaria, tachycardia, nasal/ocular symptoms. Use sedating (diphenhydramine, hydroxyzine) or non-sedating (cetirizine, loratadine) agents. Titrate to higher-than-standard doses if needed 8, 4.
• H2 antihistamines: Add ranitidine or famotidine for gastrointestinal symptoms (gastric hypersecretion, abdominal pain, diarrhea) and to augment H1 blockade for severe pruritus 8.

Second-line (for refractory symptoms):

• Cromolyn sodium: Effective for gastrointestinal symptoms (diarrhea, abdominal pain, nausea) and may help cutaneous and neurologic symptoms (brain fog, headache) 4.
• Leukotriene receptor antagonists: For skin and GI symptoms not responding to antihistamines 4.
• Proton pump inhibitors: If H2 blockers inadequately control gastric symptoms 8.

Third-line:

• Aspirin: For symptoms associated with elevated prostaglandin levels (flushing). Caution: Can trigger mast cell activation in some patients—use only after careful assessment 4.
• Corticosteroids: For severe refractory symptoms, use as-needed rather than chronically 4.
• Omalizumab: Anti-IgE antibody for symptoms insufficiently controlled by other antimediator therapy 4.

3. Emergency Management

All patients must carry two epinephrine auto-injectors 4. For acute mast cell activation with hypotension, wheezing, or laryngeal edema, administer epinephrine intramuscularly in recumbent position immediately 8.

During anaphylaxis:

• Discontinue suspected trigger
• Epinephrine IM (repeat every 5-15 minutes as needed)
• Aggressive fluid resuscitation with crystalloids
• H1 and H2 antihistamines as adjuncts
• Corticosteroids as adjuncts
• Check serum tryptase 30-120 minutes after symptom onset and after recovery 4

Special Situations

Perioperative Management

Mast cell activation during surgery is a significant risk 4. Multidisciplinary planning with surgery, anesthesia, and perioperative teams is mandatory 4.

Preoperative preparation:

• Review prior anesthetic records
• Identify/avoid known triggers
• Premedicate with benzodiazepines (anxiolysis), H1/H2 antihistamines, and possibly corticosteroids 4

Safer perioperative agents (based on anecdotal evidence) 4:

• Induction: Propofol
• Inhalational: Sevoflurane, isoflurane
• Analgesics: Fentanyl, remifentanil
• Local anesthetics: Lidocaine, bupivacaine
• Muscle relaxants: Rocuronium, vecuronium (avoid atracurium, mivacurium, succinylcholine)

Critical caveat: Do not withhold analgesics—pain itself triggers mast cell activation 4.

Pregnancy

SM does not affect fertility and is not a contraindication to pregnancy 4. However, 20-30% experience spontaneous miscarriages or symptom worsening 4.

Management requires high-risk obstetrics and anesthesia involvement 4:

• Continue trigger avoidance
• Prophylactic antihistamines (H1/H2)
• Corticosteroids as-needed
• Epinephrine on-demand for anaphylaxis
• For severe refractory SM: Consider interferon-alfa (avoid cladribine, tyrosine kinase inhibitors) 4

Pediatric Mastocytosis

Cutaneous mastocytosis in children has excellent prognosis with high spontaneous regression rates 8. Cytoreductive therapy is strongly discouraged except for life-threatening cases 8.

Management priorities 8:

• Parent/caregiver education is essential
• Inform schools, daycare, pediatricians about diagnosis and emergency protocols
• Baseline serum tryptase (>20 μg/L warrants close observation)
• Symptoms typically most severe in first 6-18 months after lesion onset
• H1 antihistamines for pruritus, flushing, urticaria
• Combined H1/H2 for severe symptoms
• Cromolyn sodium for GI symptoms
• Epinephrine for acute severe reactions

Cytoreductive Therapy

Reserved for advanced systemic mastocytosis (ASM, SM-AHN, MCL) due to organ damage and shortened survival 4.

First-line options for advanced SM 4:

• Midostaurin: KIT inhibitor, starting dose 100 mg twice daily with food
• Cladribine: Purine analog
• Imatinib: Only if KIT D816V-negative or FIP1L1-PDGFRA fusion present
• Interferon-alfa (standard or pegylated) ± prednisone

For ISM/SSM, cytoreductive therapy may be considered only for severe refractory mediator symptoms or bone disease unresponsive to antimediator therapy and bisphosphonates 4.

Allogeneic hematopoietic cell transplantation should be evaluated for patients with advanced SM showing adequate response to cytoreductive therapy with suitable donors identified 4.

Key Clinical Pitfalls

1. Not recognizing non-IgE triggers: Mast cell activation occurs through multiple pathways beyond allergies 5. Consider mastocytosis/MCAS even without positive allergy testing.

2. Inadequate epinephrine access: Patients need TWO auto-injectors at all times—one may be insufficient for severe reactions 4.

3. Withholding necessary medications perioperatively: While caution is warranted, pain and anxiety themselves trigger mast cell activation. Adequate analgesia and anxiolysis are protective 4.

4. Overdiagnosing MCAS: Requires strict criteria including documented mediator elevation and response to antimediator therapy 3. Many patients with non-specific symptoms do not have true MCAS.

5. Using cytoreductive therapy in pediatric cutaneous mastocytosis: Almost never indicated given benign natural history 8.

6. Missing hereditary alpha-tryptasemia: Consider in patients with elevated baseline tryptase and multisystem symptoms without meeting mastocytosis criteria 4.